importance of the serum LOX-1 levels in the diagnosis and assessment of left ventricular systolic heart failure and its relationship with serum pro-BNP. Methods: Fifty-five patients with a diagnosis of systolic heart failure and 25 patients without systolic heart failure were enrolled in this study. The study took place in the department of cardiology at Uludag University School of Medicine between October 2011 and April 2012. Echocardiography was performed in all cases. Serum C-reactive protein, pro-BNP and LOX-1 levels were studied. Results: Serum LOX-1 and pro-BNP levels were significantly higher in the heart failure group and showed negative correlations with left ventricular ejection fraction. However, there was no significant correlation between serum LOX-1 and pro-BNP levels. In addition, LOX-1 level in patients with ischemic cardiomyopathy was significantly higher than the patients with dilated cardiomyopathy. ROC analysis was done for the studied sample of serum LOX-1, the 'cut off' level was determined as 1.31 ng/ml for LOX-1 giving a sensitivity of 56.3% and specificity of 96% for the diagnosis of the systolic heart failure. Conclusion: Our study demonstrates the utility of the serum LOX-1 levels in the diagnosis of left ventricular systolic heart failure. LOX-1 may have an important place in the diagnosis of heart failure, especially when the etiology is ischemic cardiomyopathy. Further prospective studies with larger sample sizes are needed to better understand the exact role of LOX-1 in the diagnosis and assessment of heart failure.
Methods: Two hundred and nineteen patients (168 male, 51 female, mean age 63.2AE12.7 years) with acute exerbation of advanced heart failure (ejection fraction 35%) were included in this study. Levosimendan was initiated as a bolus of 6 mg/kg followed by a continuous infusion of 0,1 mg/kg/min for 24 hours. Changes of hematological variables between admission and on third day after levosimendan infusion were evaluated. Categorical variables were expressed as frequencies and percentages. Continuous variables were compared using analysis of variance and Kruskal-Wallis tests for those with normal and skewed distributions, respectively. Chi-square tests were used to compare categorical variables. Univariate and multivariate Cox regression models were used to evaluate the independent association of different hematological variables with in-hospital mortality. Results: Table 1 demonstrated the baseline demographical and laboratory characteristics of the patients. After levosimendan therapy, significant decrease in WBC and neutrophil counts and increase in lymphocyte count. As a result, neutrophil to lymphocyte ratio (NLR) decreased. Compared to patients that survived, in patients who died during in-hospital stay, these hematological changes not occurred (Table 2 ). D NLR detected as independent predictor of in hospital mortality when other hematological variables associated with mortality analysed in the multivariate logistic regression analysis (R2¼0.094, p¼0.003). Conclusion: Our study showed that levosimendan treatment is associated with significant changes in hematological variables in patients with acute exacerbation of advanced heart failure. The difference between baseline and post-treatment NLR is independent predictor of in hospital mortality.
OP-168
Post-discharge Heart Failure Monitorization Program in Turkey: Hit-PoinT Introduction: The middle-term results of VSD closure using different devices in our clinic are presented. Patients and Methods: Patients undergoing transcatheter VSD closure in our clinic between April 2007 and June 2013 were reviewed. Defects were closed in cases with a large VSD on echocardiography, left chamber hypertrophy and hemodynamically a Qp/Qs>1.5 and/or reversible pulmonary hypertension. In perimembranous VSD the left disk of the occluder was placed on the left of the septum in the absence of aneurysm. If an aneurysm was present, the left disk was placed inside it, to reduce the risk of AV block. Results: Median age of the patients was 8 (range, 10 months -55 years); their average follow-up was 37AE20 months and average Qp/Qs 2.0AE0.63. Average VSD diameter was 91AE3 mm (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) . Implantation was successful in 74 (92.5%) of the 80 patients. Of these, 51 had perimembranous and 23 muscular defects. For cases with perimembranous defects, an eccentric Amplatzer perimembranous VSD device was placed in 18, a Cardiofix muscular VSD device in 17, an Amplatzer or Cardiofix duct occluder in 9, an Amplatzer muscular VSD device in 3, a Lifetech muscular VSD device in another 3 and an ADOII device in one patient. The device was placed within the aneurysm tissue in 18 cases. As for muscular VSD, Cardiofix muscular VSD device was used in 18 patients, an Amplatzer muscular VSD device in 2, a Lifetech muscular VSD in another 2 and a Cardiofix ASD occluder in one patient. Complete occlusion immediately post-intervention was achieved in 52% (39/74), 70% (52/74) on the next day and 85% (63/74) at the 6-month follow-up. The residual defect ratio was significantly higher where the device had been placed inside the aneurysm (p<0.05). One patient had a reversible complete AV block and another one experienced hemolysis, no other major complications were observed. One patient underwent open surgery for a significant residual defect. During follow-up, two patient had de novo presentation of non-progressive, minimal aortic insufficiency. Conclusion: VSD occlusion by different devices is safe and efficacious in selected patients. While placement of the device inside the aneurysm increases the proportion of residual shunt, it is believed that it may reduce the risk of AV block, the most feared complication.
OP-170
Percutaneous Closure of Perimembranous Ventricular Septal Defects Associated With Septal Aneurysm Oktay Ergene 1 , Nihan Kahya Eren 2 , Hamza Duygu 2 , U gur Kocabaş 2 , Cem Nazlı 2 1 Dokuz Eylul University, Faculty of Medicine, Cardiology Department, Izmir, 2 Izmir Katip Celebi University Ataturk Education and Research Hospital, Cardiology Department, Izmir Introduction: Ventricular septal defects (VSD) are the most common congenital heart disease. Of these defects 80% involves the membranous septum. With the introduction of eccentric perimembranous VSD (PmVSD) occluder devices, percutaneous closure of PmVSDs has become an accepted alternative to surgical closure. However, closure of PmVSDs associated with septal aneurysms is more challenging. We report our experience of device closure of PmVSD associated with septal aneurysm. Material-Methods: Between 2008 and 2012, percutaneous closure of PmVSD associated with a septal aneurysm was attempted in 11 patients in our institution. The indication for VSD closure was the presence of hemodynamically significant PmVSD demonstrated by cardiac catheterisation (Qp/Qs > 1.5). We used 2 methods to occlude PmVSD associated with septal aneurysm: 1) to close the defect at the left ventricular opening of the aneurysm by anchoring the left disc of the occluder at the the inlet portion of the aneurysm and compressing the aneurysm and the defect between the left and the right discs of the device; 2) to close the defect at the outlet by anchoring the left disc of the device at the left side of the outlet portion of the aneurysm. We preferred to use the first method when the aneursym was small and there is adequate distance from the aortic valve. The patients were followed up at 1st, 3rd, 6th and 12th months after the closure procedure by TTE and ECG. Results: Mean age of the patients was 36.2AE1.3 and 64% were male. The demographic and clinical characteristics of patients are shown in table 1. The average diameter of the VSD was 5.9AE2.4 mm by angiography. One patient had 2 defects within the aneurysm and 1 patient had dextrocardia. Large aneurysm (the inlet portion of the aneurysm > 10 mm) was present in 7 patients. The procedure was successful in all patients. We used Amplatzer PmVSD occluder device in 3 patients, Amplatzer Muscular VSD occluder device in 5 patients, Amplatzer Duct occluder-I (ADO-I) in 1 patient and ADO-II device in 2 patients. We prefered to occlude the defect by the first method in 4 patients who had a small aneurysm and PmVSD occluder was used in 3 cases and a muscular VSD occluder device was implanted in 1 patient. Second method was prefered in 7 patients who had larger aneurysms. A trivial residual shunt was detected by ventriculography in 4 patients immediately after the procedure. Complete closure was observed by transthoracic echocardiography in all patients at the time of discharge. The patients were followed-up at mean of 22AE1.9 months. There was no device or procedure related complications at the acute setting or midterm follow-up. Conclusion: Percutaneous closure of PmVSDs associated with aneurysm is more challenging than simple defects. The selection of the device type and size should be made according to the configuration and size of the aneurysm and the defect. 
Demographic and clinical characteristics of patients

